Info

Indevus Pharmaceuticals, Inc. (Indevus) is a pharmaceutical company engaged in the acquisition, development and commercialization of products to treat conditions in urology and endocrinology. The Company’s products include SANCTURA and SANCTURA XR for overactive bladder (OAB), which it co-promotes with its partner Allergan, Inc. (Allergan), VANTAS for advanced prostate cancer, SUPPRELIN LA for central precocious puberty (CPP), and DELATESTRYL for the treatment of hypogonadism. Indevus’s core urology and endocrinology portfolio contains multiple compounds in development in addition to its approved products. Its most advanced compounds are NEBIDO for male hypogonadism, VALSTAR for bladder cancer, PRO 2000 for the prevention of infection by human immunodeficiency virus (HIV) and other sexually-transmitted diseases, the octreotide implant for acromegaly and a biodegradable ureteral stent used in association with the treatment of kidney stones.(Source: 10-K)